Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 12Myeloproliferative Disorders 3Myelodysplastic Syndromes 2Leukemia, Monocytic, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 85fludarabine phosphate 84Peripheral Blood Stem Cell Transplantation 70Mycophenolic Acid 58Tacrolimus 57Whole-Body Irradiation 55Busulfan 54Antilymphocyte Serum 47Cyclosporine 45Methotrexate 38fludarabine 37Filgrastim 37Melphalan 32Radiotherapy 27Cytarabine 27Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Azacitidine 18Sirolimus 15Granulocyte Colony-Stimulating Factor 15Flow Cytometry 14Cyclosporins 14thymoglobulin 13Specimen Handling 13Alemtuzumab 13Biopsy 12venetoclax 10Thiotepa 10Decitabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Liposomes × Other hematologic neoplasm × Clear all
NCT05554406 2026-06-05

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
335 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡